The AANS is expected to host a lot more than 6.
Related StoriesResearchers recognize potential brain-based biomarker for depressive symptomsSwedish measurement solution to be used as standard in Alzheimer's diagnostics worldwideStudy: Eating lovely foods causes the brain to form memories that may control feeding on behaviorsThe keynote speaker is Cushing Orator Newt Gingrich, PhD, on Tuesday, May 3, 12:01 pm. As Speaker of the United States House of Representatives from 1995 to 1999, he disrupted the position quo by shifting power out of Washington and back again to the American people.Blatt, Ph.D., Chief and Founder Executive Officer of Alios BioPharma. ‘For more than a 10 years, Vertex is a leader in the advancement of new approaches for treating hepatitis C, and together we have the potential to develop an all-oral, interferon-free, mixture therapy that could enhance the safety, efficacy and simple administration for patients. We anticipate initiating clinical development later this year.’ ‘The recent authorization of INCIVEK was a milestone in hepatitis C treatment, and today’s announcement underscores our long-term commitment to further improving the treatment of this disease with fresh combinations of medicines,’ said Peter Mueller, Ph.D., Chief Scientific Executive and Officer Vice President of Global Analysis and Development at Vertex.